Definium Therapeutics, Inc. (MMED.CA) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Vancouver, Canada. The company went public in 2016 and focuses on developing novel therapeutic treatments for brain health disorders including psychiatry, addiction, pain, and neurology. MindMed is at the forefront of psychedelic medicine research, developing treatments based on compounds like LSD and MDMA that have shown promise in addressing mental health conditions that affect millions of people worldwide.

Ask drillr about Definium Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−353.79M

Op. CF (TTM)

−166.87M

Latest newsMore news →

The U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.5d ago

Definium Therapeutics reported that its LSD-based therapy DT120 eased anxiety in a second late-stage trial, with patients on a 100-microgram dose showing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo.6d ago

Latest newsMore news →

The U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.5d ago Definium Therapeutics reported that its LSD-based therapy DT120 eased anxiety in a second late-stage trial, with patients on a 100-microgram dose showing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo.6d ago Definium Therapeutics announced six poster presentations at Psych Congress 2026, taking place September 15-19 in New Orleans, covering topline Phase 3 data from the Emerge and Voyage trials of DT120 Orally Disintegrating Tablet in major depressive disorder and generalized anxiety disorder.10d ago